Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Titan Pharmaceuticals Inc is a biotechnology business based in the US. Titan Pharmaceuticals shares (TTNP) are listed on the NASDAQ and all prices are listed in US Dollars. Titan Pharmaceuticals employs 12 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Long-term investors
Our top pick for
Beginners
Our top pick for
Active traders
| Latest market close | $0.99 |
|---|---|
| 52-week range | $0.97 - $4.61 |
| 50-day moving average | $1.29 |
| 200-day moving average | $2.01 |
| Wall St. target price | $7.00 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | $-1.07 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.99 from 2022-01-20
| 1 week (2022-01-13) | -0.10% |
|---|---|
| 1 month (2021-12-18) | N/A |
| 3 months (2021-10-20) | -45.26% |
| 6 months (2021-07-22) | -57.33% |
| 1 year (2021-01-22) | -68.97% |
|---|---|
| 2 years (2020-01-21) | 166.13% |
| 3 years (2019-01-18) | 321.28% |
| 5 years (2017-01-20) | 4.15 |
| Revenue TTM | $2.8 million |
|---|---|
| Gross profit TTM | $-1,550,000 |
| Return on assets TTM | -65.24% |
| Return on equity TTM | -205.09% |
| Profit margin | 0% |
| Book value | $0.76 |
| Market capitalisation | $10 million |
TTM: trailing 12 months
We're not expecting Titan Pharmaceuticals to pay a dividend over the next 12 months.
Titan Pharmaceuticals's shares were split on a 1:30 basis on 30 November 2020. So if you had owned 30 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Titan Pharmaceuticals shares – just the quantity. However, indirectly, the new 2900% higher share price could have impacted the market appetite for Titan Pharmaceuticals shares which in turn could have impacted Titan Pharmaceuticals's share price.
Over the last 12 months, Titan Pharmaceuticals's shares have ranged in value from as little as $0.97 up to $4.61. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Titan Pharmaceuticals's is 0.7354. This would suggest that Titan Pharmaceuticals's shares are less volatile than average (for this exchange).
Titan Pharmaceuticals, Inc. , a pharmaceutical company, develops therapeutics for the treatment of chronic diseases. It develops products based on ProNeura, a proprietary long-term drug delivery platform that focuses primarily on the treatment for chronic diseases. The company offers Probuphine implant for the maintenance treatment of opioid use disorder in clinically stable patients in Canada and the European Union. It is also developing kappa opioid agonist peptide program, TP-2021 for use in combination with ProNeura technology for treatment of chronic pruritus; nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder; and other programs, including non-clinical evaluation of the ProNeura platform in malaria prophylaxis. Titan Pharmaceuticals, Inc. was incorporated in 1992 and is based in South San Francisco, California.
Melania Trump launched an NFT platform — you can buy an image of her eyes.
Read our expert analysis on Vigorus and how the token will perform in the future.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Starting Jan. 18, every household can order up to four free at-home COVID-19 tests. But you’ll have to wait for them.
While there are no known plans to expand the acceptance of Doge to its cars, customers can already buy a Tesla with Bitcoin.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
See the 10 biggest gainers on the New York Stock Exchange and Nasdaq.
Donut earns up to 10% APY, but you must have an iOS device.
We’ve rounded up stats on some of the most popular COVID test stocks, along with information on how they compare and how to invest.
Buffett’s Berkshire Hathaway may now be on its way to becoming the next trillion-dollar company.
